Should a patient with HBV-DNA over 10,000 IU/ml receive antiviral therapy?

Evidence shows that patients with CHB and HBV-DNA over 10,000 IU/ml should receive antiviral therapy due to its efficacy in reducing viral load and lowering the risk of liver disease complications.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24341145
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Should a patient with HBV-DNA over 10,000 IU/ml receive antiviral therapy?

Tripdatabase
Zenodo (CERN European Organization for Nuclear Research)
Hepatitis B Virus Studies
article

Should a patient with HBV-DNA over 10,000 IU/ml receive antiviral therapy?

Tripdatabase
article en

Abstract

Evidence shows that patients with CHB and HBV-DNA over 10,000 IU/ml should receive antiviral therapy due to its efficacy in reducing viral load and lowering the risk of liver disease complications.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon